Clinical Trials Logo

Filter by:
NCT ID: NCT02145208 Completed - Clinical trials for Benign Prostatic Hyperplasia (BPH)

Study to Assess the Efficacy of Medi-Tate iTind Device

Start date: October 2014
Phase: N/A
Study type: Interventional

The study will include an implantation of the iTind device and 4 follow up visits up to 12 months after the implantation.

NCT ID: NCT02145182 Completed - Clinical trials for Delayed Graft Function

Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)

Start date: August 21, 2014
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study was to determine if eculizumab is safe and could be used to prevent delayed graft function (DGF) following kidney transplantation.

NCT ID: NCT02144987 Completed - Asherman's Syndrome Clinical Trials

Bone Marrow Stem Cell Treatment for Asherman's Syndrome and Endometrial Atrophy

BMSCT
Start date: April 2013
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether Bone Marrow Stem Cell transplantation may improve Assisted Reproduction Techniques (ART) outcomes in refractive Asherman's Syndrome or Atrophic Endometrium.

NCT ID: NCT02143791 Completed - Chronic Pain Clinical Trials

Evaluate St Jude Medical Prodigy Neuromodulation for FBSS or Chronic Pain of the Trunk and/or Limbs

Prodigy-I
Start date: June 2014
Phase: N/A
Study type: Observational

The purpose of this study is to confirm long term efficacy and safety of the ProdigyTM neuromodulation system in the management of failed back surgery syndrome or chronic intractable pain of the trunk and/or limbs.

NCT ID: NCT02143778 Completed - Clinical trials for Patients With Compensated Liver Cirrhosis

Assessing Portal Hypertension With Methacetin Breath Test

Start date: November 2014
Phase: N/A
Study type: Interventional

This study will be used to train an algorithm using Methacetin breath test (MBT) measures and to select a cut-off to determine presence or absence of Clinically Significant Portal Hypertension (CSPH) as defined by Hepatic Venous Gradient Pressure (HVPG) ≥ 10mmHg,

NCT ID: NCT02143635 Completed - Clinical trials for Advanced Solid and Hematological TP53wt Tumors

Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt

Start date: July 7, 2014
Phase: Phase 1
Study type: Interventional

To determine and evaluate a safe and tolerated dose of HDM201 in adult patients with selected advanced tumors characterized by wild-type TP53.

NCT ID: NCT02142751 Completed - Clinical trials for Infection Due to ESBL Escherichia Coli

Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.Coli

FOREST
Start date: July 2014
Phase: Phase 3
Study type: Interventional

Enterobacterieaceae (and specially Escherichia coli) showing resistance due to multidrug-resistant Escherichia coli, plasmid mediated AmpC or quinolone resistance caused by chromosomal mechanisms have spread worldwide during the last decades. This is important because many of these isolates are also resistant to other first-line agents such as fluoroquinolones or aminoglycosides, leaving few available options for therapy, and this condition is associated with increased morbidity- mortality and length of hospital stay. While carbapenems are considered the drugs of choice for multidrug-resistant Escherichia coli and AmpC producers, recent data suggests that certain alternatives may be suitable for some types of infections. At the present time, finding therapeutic alternatives to carbapenems and cephalosporins for the treatment of invasive infections due to multidrug-resistant Escherichia coli is critical. Fosfomycin was discovered more than 40 years ago but was not investigated according to present standards, and thus is not used in clinical practice except in desperate situations. It is one of the so-considered neglected antibiotics with high potential interest for the future. With the aim of demonstrate the clinical non-inferiority of intravenous fosfomycin compared to meropenem or ceftriaxone in the treatment of bacteraemic urinary tract infections caused by multidrug-resistant Escherichia coli . The investigators propose a "real practise" randomised, controlled, multicentre phase III clinical trial to compare the clinical and microbiological efficacy and safety of intravenous fosfomycin (4 grammes every 6 hours) with meropenem (1 gramme every 8 hours) or ceftriaxone (1 gramme every 24 hours) as targeted therapy of the previously specified infection; change to oral therapy according to predefined options is allowed in both arms after 5 days. Follow-up for the study is planned up to 60 days.

NCT ID: NCT02142361 Completed - Astigmatism Clinical Trials

Clinical Performance of Habitual Hydrogel vs. Silicone Hydrogel Toric Contact Lenses

Start date: May 2014
Phase: N/A
Study type: Interventional

Evaluate the clinical performance of existing wearers of hydrogel toric lenses when refitted with Avaira toric silicone hydrogel contact lenses over 1 week of wear.

NCT ID: NCT02142283 Completed - Ischemic Stroke Clinical Trials

Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention With Trevo

DAWN
Start date: July 2014
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate the hypothesis that Trevo thrombectomy plus medical management leads to superior clinical outcomes at 90 days as compared to medical management alone in appropriately selected subjects experiencing an acute ischemic stroke when treatment is initiated within 6-24 hours after last seen well.

NCT ID: NCT02141672 Completed - Lupus Nephritis Clinical Trials

AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)

AURA-LV
Start date: June 2014
Phase: Phase 2
Study type: Interventional

To assess the efficacy of 2 doses of voclosporin compared to placebo in achieving complete remission after 24 weeks of therapy in subjects with active lupus nephritis.